Innate Pharma S.A. Sponsored ADR IPHA
1.70
0.00
0.00%
as of 25 Sep
- Market cap
- $188.8M
- P/E
- 0.0×
Follow IPHA
| Jun '26 | Dec '25 | Jun '25 | Dec '24 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
0.60 | 1.27 | 2.21 | 2.60 | |
Current Ratio |
0.60 | 1.27 | 2.21 | 2.60 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
58.19% | 35.99% | 29.08% | 27.91% | |
Debt/Equity |
(0.50) | (1.04) | 5.25 | 3.51 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(0.15) | (0.10) | (0.08) | (0.20) | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | — | |
Free Cash Flow Yield |
— | — | — | — | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(24.57) | (59.85) | (35.44) | (7.88) | |
Working Capital |
(15.41) | 11.38 | 40.36 | 57.09 | |
Capital Expenditures |
(0.10) | (0.16) | (0.07) | (0.42) | |
Net Current Asset Value |
(64.69) | (42.67) | (25.90) | (17.84) | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
15.72 | 37.08 | 33.10 | 22.89 | |
Average Payables |
15.10 | 17.72 | 17.19 | 19.68 | |
Average Assets |
101.76 | 135.16 | 161.27 | 169.59 | |
Average Common Equity |
(8.04) | 15.81 | 34.47 | 33.31 |
Columns are period end dates